Sophia Genetics reported a 16 percent year-over-year revenue increase for Q2 2025, fueled by robust molecular analyses on its AI-driven platform. The company announced an expanded multi-year collaboration with AstraZeneca to leverage Sophia's multimodal AI technologies for breast cancer research, including integrating genomics, imaging, and clinical data to generate real-world evidence. Despite wider operational losses, the company expects to realize revenue milestones from the partnership starting Q4 2025.